ClinicalTrials.gg
Not yet recruitingNCT05616078Updated Nov 15, 2022

Laser Versus Cryotherapy for the Treatment of Recalcitrant Warts

An interventional study of laser treatment and cryotherapy in Warts, sponsored by The 306 Hospital of People's Liberation Army. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-15.

Sponsored by The 306 Hospital of People's Liberation Army · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate whether laser was superior to cryotherapy for recalcitrant warts

Read the detailed description

Patients with recalcitrant warts were randomized equally to receive laser or cryotherapy every 3 to 4 weeks, for a maximum of 4 sessions.The primary outcomes were the cure rate at 16 weeks; secondary outcomes included time to clearance of warts, patient satisfaction with the treatment and treatment-related adverse effects.

02

Conditions studied

  • Warts

Browse trials for

03

In context

Warts

171 studies on the registry are indexed under Warts; 35 are open to participants now.

This study's planned enrollment of 110 is above the median of 70 across 155 interventional studies indexed under Warts.

Browse Warts studies →

Lead sponsor

The 306 Hospital of People's Liberation Army is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with HPV2/27/57-induced recalcitrant warts, including periungualor mosaic warts, common or plantar warts with a duration of longer than 1 year, and common or plantar warts previously received no more than two sessions of cryotherapy
  • Total number of warts is ≤10 .
  • Aged 18 years or older.

Exclusion criteria

Exclusion Criteria:

  • Patients are currently participating in another trial for the treatment of cutaneous warts.
  • Patients have taken drugs (such as oral ) during the past three months.
  • Patients have impaired healing eg due to diabetes, vitamin A deficiency, hyperthyroidism and hypothyroidism.
  • Patients have diseases (such as systemic lupus erythematosus, dermatomyositis, scleroderma or other diseases).
  • Patients are pregnant or ready for pregnancies or breast-feeding.
  • Patients have cold intolerance (such as cold urticaria, cryoglobulinaemia, cold agglutinin syndrome or Raynaud's syndrome).
  • Patients have local pain intolerance.
  • Patients have local hypoesthesia.
  • Patients are unable to tolerate laser or cryotherapy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    laser treatment

    LP-Nd:YAG laser treatment

    Other: laser treatment

  • Active comparator
    cryotherapy

    cryotherapy with liquid nitrogen

    Other: cryotherapy

Interventions

  • Otherlaser treatment

    a maximum of 4 sessions, with an interval of 3 to 4 weeks

  • Othercryotherapy

    a maximum of 4 sessions, with an interval of 3 to 4 weeks

06

What researchers measure

Primary outcomes

  1. cure rate at 16 weeks

    A patient was considered to be cured if all warts were no longer visible and could not be palpated anymore.

    Time frame: 16 weeks since the initial treatment

Secondary outcomes

  1. time to clearance of warts

    The time from treatment initiation until clearance of all warts

    Time frame: 16 weeks since the initial treatment

  2. patient satisfaction with the treatment

    Patient satisfaction was rated on a 5-point scale (from very happy to very unhappy)

    Time frame: 16 weeks since the initial treatment

  3. treatment-related adverse events

    Some adverse effects, including pain, swelling, blisters, hemorrhagic bullae, bruising, and skin breakdown, were recorded by the patients, whereas others, including secondary bacterial infection, hyperpigmentation, hypopigmentation, and scarring were evaluated by a dermatologist

    Time frame: 16 weeks since the initial treatment

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05616078
Lead sponsor
The 306 Hospital of People's Liberation Army
Responsible party
Sponsor
First posted
Nov 15, 2022
Start date
Nov 2022 (estimated)
Primary completion
Nov 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Nov 15, 2022

Study contacts

Shichao Lu, MD
Contact
lvshichao@sina.com
8610-010-66356984
Shichao Lu, MD
principal investigator · The 306 Hospital of People's Liberation Army

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion